Accordingly, we suggest that prostate PSMA-TV levels over 8.1 are mainly useful as a ‘rule-in’ tool for stricter follow-up and treatment approaches in patients who do not have metastases found in their initial PET-CT but should be a part of a high-risk group for developing metastatic disease. The gene discussed is FOLH1; the disease is metastatic neoplasm.